KRAS and cancer: Clinically, 17 of 38 patients (45%) explored by Awad et al. with G12C mutant cancers exhibited some form of acquired resistance and among those, the secondary KRAS mutations (Y96C, G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/Q) were found in 4 patients and resulted in resistance to adagrasib [53].